Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01790113 · ClinicalTrials.gov registry record · NA

Arthrex Eclipse™ Shoulder Prosthesis

A NA study, sponsored by Arthrex.

Terminated
Registry status
NA
Development phase
303
Enrollment target

NCT01790113: Clinical Trial NA study, sponsored by Arthrex.

NCT01790113 is a NA study that was terminated before completion, run by Arthrex. The registered enrollment target is 303 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01790113, a NA study, was terminated before completion, sponsored by Arthrex.

TERMINATED
Registry status
NA
Development phase
303 participants
Enrollment target

Study Summary

A Prospective, Randomized, Multicenter Study comparing the Safety and Effectiveness of Arthrex's Eclipse™ Shoulder to the Univers™ II Shoulder Prosthesis in patients with a degenerative joint disease.

Primary Outcome

To be considered a success, the eclipse subject must meet the following composite clinical success criteria: 1. An improvement in the Adjusted Constant Score (for pain, Function, and range of motion) from baseline (pre-op) to the 24 month time-point that is \> or = to 10 and a final Adjusted Constant Score \> or + to 54. 2. Radiographic success at the Month 24 time-point which is defined as absence of clinically significant humeral radiolucency, humeral migration/subsidence (relative to 3 month

Interventions

  • DEVICE Univers™
  • DEVICE Eclipse™ Total Shoulder Replacement

Trial Details

FieldValue
Enrollment Target 303 participants
Start Date 2013-02-04
Est. Completion 2019-06-07
Phase NA
Arthrex

12 total trials

Why NCT01790113 stopped before completion

NCT01790113 is an interventional study that assigns participants to a tested intervention. The registered 303 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (78% lower).

The record links to 0 conditions, and to 2 interventions - of which Univers™ is the first listed.

NCT01790113 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01790113 about?

NCT01790113 is a clinical study titled "Arthrex Eclipse™ Shoulder Prosthesis". A Prospective, Randomized, Multicenter Study comparing the Safety and Effectiveness of Arthrex's Eclipse™ Shoulder to the Univers™ II Shoulder Prosthesis in patients with a degenerative joint disease.

What is the current status of trial NCT01790113?

This trial is currently terminated. It is a NA study. The enrollment target is 303 participants. The study started on 2013-02-04. Estimated completion is 2019-06-07.

What interventions are being tested in trial NCT01790113?

The interventions under investigation include: Univers™ (DEVICE), Eclipse™ Total Shoulder Replacement (DEVICE).

Who is sponsoring clinical trial NCT01790113?

This trial is sponsored by Arthrex, which has 12 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01790113's enrollment target sits among peer trials

303 329th of 2000 higher than 1,671 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05508971 · 303 participants · NA

    Treatment of Obstructive Sleep Apnea With Personalized Surgery in Children With Down Syndrome (TOPS-DS)

  • NCT04750616 · 304 participants · Phase 2

    NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial

  • NCT04994717 · 304 participants · Phase 3

    Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia

  • NCT06036147 · 304 participants · NA

    Concussion Health Improvement Program

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01790113, the US trial registry maintained by the National Library of Medicine. NCT01790113 (mid enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.